Real-World study tracks tucatinib combo for tough breast cancer

NCT ID NCT05253911

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well the drug tucatinib (Tukysa) works in everyday medical practice for people with advanced HER2-positive breast cancer who had already tried at least two other treatments. Researchers tracked 49 adults in Germany and Austria to see how their quality of life changed and how long it took for their cancer to worsen. The goal was to understand the real-world benefits of adding tucatinib to standard therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Medizinische Universität Wien, Innere Medizin I, Hämatologie und Onkologie

    Vienna, 1090, Austria

  • Universitätsklinikum Essen, Innere Klinik (Tumorforschung)

    Essen, North Rhine-Westphalia, D-45112, Germany